{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:33:54Z","timestamp":1794062034030,"version":"4.8.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.2169\/internalmedicine.8439-21","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T22:11:22Z","timestamp":1635199882000},"page":"1707-1712","source":"Crossref","is-referenced-by-count":3,"title":["Bilateral Serous Retinal Detachment Associated with a Mitogen-activated Protein KinaseKinase Inhibitor in a Patient with &lt;i&gt;BRAF&lt;\/i&gt;-mutant Colorectal Cancer"],"prefix":"10.2169","volume":"61","author":[{"given":"Miho","family":"Sakumura","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ueda-Consolvo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iori","family":"Motoo","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mihara","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohachi","family":"Nanjo","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Fujinami","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Toyama University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2559.2006.02549.x","volume":"50","author":"JR Jass","year":"2007","unstructured":"1. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50: 113-130, 2007.","journal-title":"Histopathology","ISSN":"https:\/\/id.crossref.org\/issn\/0309-0167","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104: 856-862, 2011.","DOI":"10.1038\/bjc.2011.19"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Phipps AI, Buchanan DD, Makar KW, et al. <i>BRAF<\/i> mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 21: 1792-1798, 2012.","DOI":"10.1158\/1055-9965.EPI-12-0674"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29: 44-70, 2018.","DOI":"10.1093\/annonc\/mdx738"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sanz-Garcia E, Argiles G, Elez E, Tabernero J. <i>BRAF<\/i> mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol 28: 2648-2657, 2017.","DOI":"10.1093\/annonc\/mdx401"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Booth AEC, Hopkins AM, Rowland A, Kichenadasse G, Smith JR, Sorich MJ. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy. Ther Adv Med Oncol 12: 1758835920944359, 2020.","DOI":"10.1177\/1758835920944359"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in <i>BRAF<\/i> V600E-mutated colorectal cancer. N Engl J Med 381: 1632-1643, 2019.","DOI":"10.1056\/NEJMoa1908075"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated <i>BRAF<\/i> V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 39: 273-284, 2021.","DOI":"10.1200\/JCO.20.02088"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. de la Cruz-Merino L, Di Guardo L, Grob JJ, et al. Clinical features of serous retinopathy observed with cobimetinib in patients with <i>BRAF<\/i>-mutated melanoma treated in the randomized coBRIM study. J Transl Med 15: 146, 2017.","DOI":"10.1186\/s12967-017-1246-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with <i>BRAF<\/i>-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19: 1315-1327, 2018.","DOI":"10.1016\/S1470-2045(18)30497-2"},{"key":"11","unstructured":"11. Francis JH, Habib LA, Abramson DH, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 124: 1788-1798, 2017."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer. JAMA Ophthalmol 134: 855-862, 2016.","DOI":"10.1001\/jamaophthalmol.2016.0090"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. McCannel TA, Chmielowski B, Finn RS, et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol 132: 1005-1009, 2014.","DOI":"10.1001\/jamaophthalmol.2014.976"},{"key":"14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","volume":"39","author":"S M\u00e9ndez-Mart\u00ednez","year":"2019","unstructured":"14. M\u00e9ndez-Mart\u00ednez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with MEK inhibitors. Retina 39: 1435-1450, 2019.","journal-title":"Retina","ISSN":"https:\/\/id.crossref.org\/issn\/0275-004X","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jiang Q, Cao C, Lu S, et al. MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med 23: 771-777, 2009.","DOI":"10.3892\/ijmm_00000191"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 39: 664-672, 2013.","DOI":"10.1016\/j.ctrv.2013.01.003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Abdel-Rahman O, Fouad M. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis. Crit Rev Oncol Hematol 93: 127-135, 2015.","DOI":"10.1016\/j.critrevonc.2014.07.005"},{"key":"18","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"18. Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4: e000491, 2019.","journal-title":"ESMO Open","ISSN":"https:\/\/id.crossref.org\/issn\/2059-7029","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ascierto PA, McArthur GA, Dr\u00e9no B, et al. Cobimetinib combined with vemurafenib in advanced <i>BRAF<\/i> (V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17: 1248-1260, 2016.","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with <i>BRAF<\/i> V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol 37: 1460-1469, 2019.","DOI":"10.1200\/JCO.18.02459"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Chancellor JR, Kilgore DA, Sallam AB, Allen RC, Uwaydat SH. A case of non-resolving MEK inhibitor-associated retinopathy. Case Rep Ophthalmol 10: 334-338, 2019.","DOI":"10.1159\/000503414"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_8439-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T03:31:52Z","timestamp":1654313512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_8439-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8439-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"8439-21"}}